Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein

Drug Metabolism and Disposition

Volumn 38, Issue 8, 2010, Pages 1286-1294

  Iwanaga, Kazunori ^a   Hayashi, Manami ^a   Hamahata, Yukimi ^a   Miyazaki, Makoto ^a   Shibano, Makio ^a   Taniguchi, Masahiko ^a   Baba, Kimiye ^a   Kakemi, Masawo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGELICOL; BERGAPTEN; CHINESE DRUG; CYCLOSPORIN A; CYTOCHROME P450 3A4; DIGOXIN; FUROCOUMARIN DERIVATIVE; GLYCOPROTEIN P; HERACELENIN; HERACLENOL; HERBACEOUS AGENT; ISOIMPERATORIN; KAMPO; KETOCONAZOLE; MIDAZOLAM; NOTOPTEROL; PLANT EXTRACT; PSORALEN; RIVULOBIRIN A; SENKYU CHA CHO SAN; SOKEI KAKKETSU TO; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHEMICAL STRUCTURE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FOOD DRUG INTERACTION; GRAPEFRUIT; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICINAL PLANT; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RUTACEAE;

ANTI-ARRHYTHMIA AGENTS; CACO-2 CELLS; CYTOCHROME P-450 CYP3A; DIGOXIN; HUMANS; MEDICINE, KAMPO; MIDAZOLAM; P-GLYCOPROTEIN; PSORALENS; QUINIDINE;

APIACEAE; CITRUS X PARADISI; RUTACEAE;

EID: 77954926944     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032847     Document Type: Article

References (46)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, and Funck-Brentano C (2001) Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70:311-316.
3. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, and Warhurst G (2005) Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci 26:386-393.
4. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287. (Pubitemid 20266126)
5. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
6. Dresser GK, Kim RB, and Bailey DG (2005) Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77:170-177.
7. Engdal S and Nilsen OG (2008) Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 38:559-573.
8. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, and Sawada Y (2006) Effect of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 34:577-582.
9. Guo LQ, Fukuda K, Ohta T, and Yamazoe Y (2000a) Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28:766-771. (Pubitemid 30470826)
10. Guo LQ, Taniguchi M, Xiao YQ, Baba K, Ohta T, and Yamazoe Y (2000b) Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn J Pharmacol 82:122-129.
11. Ito K, Suzuki H, Horie T, and Sugiyama Y (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22:1559-1577.
12. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John'sWort (Hypericum perforatum). Clin Pharmacol Ther 66:338-345.
13. Kageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, and Takada K. (2005) In vivo effect of cyclosporine A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rat. Biol Pharm Bull 28:316-322.
14. Kamath AV, Yao M, Zhang Y, and Chong S (2005) Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 94:233-239.
15. Kanazu T, Okamura N, Yamaguchi Y, Baba T, and Koike M (2005) Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A4 drug-drug interaction model rats. Xenobiotica 35:305-317.
16. Kimura Y, Shimizu M, Kohara S, Yoshii F, Sato H, and Shinohara Y (2006) Antiplatelet effects of a Kampo medicine, Orengedokuto. J Stroke Cerebrovasc Dis 15:277-282.
17. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306:703-708.
18. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, and Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878.
19. Kono T, Kanematsu T, and Kitajima M (2009) Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet? Surgery 146:837-840.
20. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, and Hall SD (2006) The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 79:218-230.
21. Lin HL, Kent UM, and Hollenberg PF (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154-164.
22. Matsuda T, Maekawa K, Asano K, and Hisamitsu T (2009) Suppressive effect of Juzen-Taiho-To on lung metastasis of B16 melanoma cells in vivo. Evid Based Complement Alternat Med doi: 1001093/eCAM/nen081.
23. Nair VD, Foster BC, Thor Arnason J, Mills EJ, and Kanfer I (2007) In vitro evaluation of human cytochrome P450 and P-glycoprotein-mediated metabolism of some phytochemicals chemicals in extracts and formulations of African potato. Phytomedicine 14:498-507.
24. Ohnishi A, Matsuo H, Yamada S, Takanaga H, Morimoto S, Shoyama Y, Ohtani H, and Sawada Y (2000) Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br J Pharmacol 130:1369-1377.
25. Omiya Y, Suzuki Y, Yuzurihara M, Murata M, Aburada M, Kase Y, and Takeda S (2005) Antinociceptive effect of shakuyakukanzoto, a Kampo medicine, in diabetic mice. J Pharmacol Sci 99:373-380.
26. Oya A, Oikawa T, Nakai A, Takeshita T, and Hanawa T (2008) Clinical efficacy of Kampo medicine (Japanese traditional herbal medicine) in the treatment of primary dysmenorrhea. J Obstet Gynaecol Res 34:898-908.
27. Paine MF, Criss AB, and Watkins PB (2004) Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 32:1146-1153.
28. Paine MF, Criss AB, and Watkins PB (2005) Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 312:1151-1160.
29. Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, and Floden J (2006) Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci 95:1984-1993.
30. Rodriguez-Proteau R, Mata JE, Miranda CL, Fan Y, Brown JJ, and Buhler DR (2006) Plant polyphenols and multidrug resistance: effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models. Xenobiotica 36:41-58.
31. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, and Tsuji A (2006) Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34:1423-1431.
32. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, and Sawada Y (2005) Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 33:518-523.
33. Schwarz UI, Gramatté T, Krappweis J, Oertel R, and Kirch W (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161-167. (Pubitemid 30193611)
34. Shimada T, Kudo T, Akase T, and Aburada M (2008) Preventive effects of Bofutsushosan on obesity and various metabolic disorders. Biol Pharm Bull 31:1362-1367.
35. Spahn-Langguth H and Langguth P (2001) Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367.
36. Sunagawa M, Okada M, Guo SY, and Hisamitsu T (2001) Effectiveness of Saiko-Keishi-To (TJ-10, a Kampo herbal medicine) for trigeminal neuralgia in rats. Masui 50:486-490.
37. Takegawa Y, Ikushima H, Ozaki K, Furutani S, Kawanaka T, Kudoh T, and Harada M (2008) Can Kampo therapy prolong the life of cancer patients? J Med Invest 55:99-105.
38. Troutman MD and Thakker DR (2003) Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1210-1224.
39. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, and Greenberg HE (2003) Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 43:831-839.
40. Wang Y, Cao J, and Zeng S (2005) Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaemperol, and isorhammetin. J Pharm Pharmacol 57:751-758.
41. Watanabe H, Zhao Q, Matsumoto K, Tohda M, Murakami Y, Zhang SH, Kang TH, Mahakunakorn P, Maruyama Y, Sakakibara I, et al. (2003) Pharmacological evidence for antidementia effect of Choto-san (Gouteng-san), a traditional Kampo medicine. Pharmacol Biochem Behav 75:635-643.
42. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
43. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, and Siegmund W (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68: 6-12.
44. Yao HM and Chiou WL (2006) The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 322:79-86.
45. Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Morimoto S, Yamaguchi N, and Kanda T (2006) Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res 34:231-239.
46. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168. (Pubitemid 32324448)